KR20240162104A - Parp 억제제로서의 치환된 트리시클릭 화합물 및 이의 용도 - Google Patents

Parp 억제제로서의 치환된 트리시클릭 화합물 및 이의 용도 Download PDF

Info

Publication number
KR20240162104A
KR20240162104A KR1020247033867A KR20247033867A KR20240162104A KR 20240162104 A KR20240162104 A KR 20240162104A KR 1020247033867 A KR1020247033867 A KR 1020247033867A KR 20247033867 A KR20247033867 A KR 20247033867A KR 20240162104 A KR20240162104 A KR 20240162104A
Authority
KR
South Korea
Prior art keywords
methyl
optionally substituted
piperazin
fluoro
methylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247033867A
Other languages
English (en)
Korean (ko)
Inventor
수이 시옹 카이
예 에드워드 티안
시아오주 왕
레티안 장
Original Assignee
임팩트 테라퓨틱스 (상하이), 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임팩트 테라퓨틱스 (상하이), 인코포레이티드 filed Critical 임팩트 테라퓨틱스 (상하이), 인코포레이티드
Publication of KR20240162104A publication Critical patent/KR20240162104A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247033867A 2022-03-11 2023-02-23 Parp 억제제로서의 치환된 트리시클릭 화합물 및 이의 용도 Pending KR20240162104A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202210260944 2022-03-11
CN202210260944.7 2022-03-11
CN202210448803.8 2022-04-24
CN202210448803 2022-04-24
CN202211219599.9 2022-09-30
CN202211219599 2022-09-30
CN202211505904.0 2022-11-28
CN202211505904 2022-11-28
PCT/CN2023/077988 WO2023169226A1 (en) 2022-03-11 2023-02-23 Substituted tricyclic compounds as parp inhibitors and the use thereof

Publications (1)

Publication Number Publication Date
KR20240162104A true KR20240162104A (ko) 2024-11-14

Family

ID=87937164

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247033867A Pending KR20240162104A (ko) 2022-03-11 2023-02-23 Parp 억제제로서의 치환된 트리시클릭 화합물 및 이의 용도

Country Status (11)

Country Link
US (1) US20250215013A1 (https=)
EP (1) EP4490161A4 (https=)
JP (1) JP2025508122A (https=)
KR (1) KR20240162104A (https=)
CN (1) CN119013279A (https=)
AU (1) AU2023229992A1 (https=)
CA (1) CA3253468A1 (https=)
IL (1) IL315586A (https=)
MX (1) MX2024011086A (https=)
TW (1) TW202400601A (https=)
WO (1) WO2023169226A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240172235A (ko) * 2022-04-28 2024-12-09 신테라, 인크. 트리시클릭 parp1 저해제 및 이의 용도

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds
JP7835895B2 (ja) * 2022-05-07 2026-03-25 サイブランチ セラピューティクス カンパニー リミテッド Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体
WO2024099416A1 (zh) * 2022-11-10 2024-05-16 上海海和药物研究开发股份有限公司 一种稠合三环类parp1抑制剂、其制备方法及用途
WO2024179547A1 (en) * 2023-03-01 2024-09-06 Impact Therapeutics (Shanghai) , Inc. Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
WO2024255697A1 (zh) * 2023-06-13 2024-12-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
TW202525808A (zh) * 2023-09-13 2025-07-01 大陸商上海瑛派藥業有限公司 用作ｐａｒｐ１抑制劑的化合物、其用途及包含其之組合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
CN101528704B (zh) * 2006-09-01 2014-04-09 生华生物科技股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
CA2672860C (en) * 2006-12-28 2013-01-29 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
CN102341394B (zh) * 2009-01-23 2015-04-15 武田药品工业株式会社 聚(adp-核糖)聚合酶(parp)抑制剂
EP2459561A1 (en) * 2009-07-30 2012-06-06 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
MX375707B (es) * 2015-06-09 2025-03-06 Onconic Therapeutics Inc Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.
US11591331B2 (en) * 2021-04-19 2023-02-28 Xinthera, Inc. PARP1 inhibitors and uses thereof
AU2022334408A1 (en) * 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
US20250163022A1 (en) * 2021-12-22 2025-05-22 Synnovation Therapeutics, Inc. Parp1 inhibitors
KR20240134366A (ko) * 2022-01-13 2024-09-09 에이스랜드 테라퓨틱스 (홍콩) 리미티드 피페라진 고리 함유 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 용도
AU2023259236B2 (en) * 2022-04-28 2025-01-09 Xinthera, Inc. Tricyclic parp1 inhibitors and uses thereof
JP7835895B2 (ja) * 2022-05-07 2026-03-25 サイブランチ セラピューティクス カンパニー リミテッド Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
WO2024099416A1 (zh) * 2022-11-10 2024-05-16 上海海和药物研究开发股份有限公司 一种稠合三环类parp1抑制剂、其制备方法及用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240172235A (ko) * 2022-04-28 2024-12-09 신테라, 인크. 트리시클릭 parp1 저해제 및 이의 용도

Also Published As

Publication number Publication date
EP4490161A1 (en) 2025-01-15
TW202400601A (zh) 2024-01-01
AU2023229992A1 (en) 2024-10-10
IL315586A (en) 2024-11-01
WO2023169226A1 (en) 2023-09-14
JP2025508122A (ja) 2025-03-21
US20250215013A1 (en) 2025-07-03
CN119013279A (zh) 2024-11-22
EP4490161A4 (en) 2026-03-11
CA3253468A1 (en) 2023-09-14
MX2024011086A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
EP4392425A1 (en) Substituted tricyclic compounds as parp inhibitors and use thereof
CN109906227B (zh) 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
KR20240162104A (ko) Parp 억제제로서의 치환된 트리시클릭 화합물 및 이의 용도
WO2022199652A1 (en) Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
EP3997087A1 (en) Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof
CN110914277B (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN119661557A (zh) 作为激酶抑制剂的二取代含氮五元杂芳基化合物及其应用
WO2022253188A1 (en) Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof
EP4419522A1 (en) Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof
WO2022218296A1 (en) Substituted fused bicyclic compounds as parp inhibitors and the use thereof
CN116670134A (zh) 取代的咪唑并[1,5-b]哒嗪化合物作为激酶抑制剂及其应用
CN110312717B (zh) 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
WO2024083237A1 (en) Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof
EP4673448A1 (en) Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
HK40115331A (zh) 作为parp抑制剂的取代的三环类化合物及其应用
HK40104162A (zh) 取代的三环类化合物作为parp抑制剂及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000